HIV-1 Env CAR-T cell therapy

This preclinical program by Cognano Inc. focuses on developing therapies for HIV-1 infection using alpaca-derived VHH antibodies (nanobodies) targeting the HIV-1 envelope glycoprotein (Env). The program encompasses two primary modalities: a VHH-based antibody therapy and a Chimeric Antigen Receptor (CAR) T-cell therapy. The VHH antibodies are engineered to bind conserved regions of the HIV-1 Env protein, which is expressed on the surface of infected cells and viral particles. In the CAR-T approach, these VHH sequences serve as the extracellular antigen-binding domain, directing T-cells to recognize and eliminate HIV-infected cells, including those in the latent reservoir. The use of nanobodies allows for the targeting of cryptic or conserved epitopes that are often inaccessible to conventional antibodies.

Other names

HIV-1 Env VHH antibodyHIV1 Env VHH antibodyHIV 1 Env VHH antibodyHIV-1 Env CAR-THIV1 Env CAR-THIV 1 Env CAR-TCognano HIV-1 Env program